MDB Capital Holdings, LLC — Q1 2024 Form 10-Q Summary
Business Context and Reporting Period
MDB Capital Holdings, LLC is a Delaware holding company with subsidiaries focused on broker-dealer and intellectual-property services, technology development, and shared administrative services. Its principal businesses include Public Ventures, a registered broker-dealer; PatentVest, an intellectual-property services provider; and Invizyne Technologies, a majority-owned synthetic-biology development company.
The filing covers the unaudited three months ended March 31, 2024, compared with the three months ended March 31, 2023. MDB reported 4,295,632 Class A shares and 5,000,000 Class B shares outstanding at March 31, 2024. Class B shares have five votes per share and are convertible one-for-one into Class A shares.
Financial Performance and Key Metrics
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Total operating income (loss), net | $(660,389) | $116,991 | $(777,380) |
| Total operating costs | $7,286,791 | $2,272,223 | +$5,014,568 |
| Net operating loss | $(7,947,180) | $(2,155,232) | $(5,791,948) |
| Interest income | $337,852 | $187,291 | +$150,561 |
| Net loss | $(7,609,328) | $(1,967,941) | $(5,641,387) |
| Net loss attributable to MDB | $(7,215,425) | $(1,873,748) | $(5,341,677) |
| Basic and diluted loss per share | $(0.78) | $(0.25) | $(0.53) |
The filing does not provide a clear consolidated revenue figure. Operating income included a $747,268 unrealized loss on broker-dealer investment securities, compared with a $54,779 unrealized gain in Q1 2023. Other operating income was $86,879, compared with $62,212.
Compensation expense increased to $4,892,675 from $872,027, primarily because of stock-based compensation and additional hiring. Total general and administrative costs increased 212.8% to $7,009,209. Research and development costs, net of grants, increased to $277,582 from $31,592. Stock-based compensation expense totaled approximately $3.81 million, including $3.67 million related to MDB and $142,810 related to Invizyne.
At March 31, 2024, total assets were $40,939,876, including $5,492,612 of cash and cash equivalents, $2,959,994 of segregated cash, $21,381,362 of U.S. Treasury bills at amortized cost, and $4,999,237 of broker-dealer investments at fair value. Total liabilities were $7,416,294, and total equity was $33,523,582. The company also reported $2,339,955 of operating lease liabilities.
Net cash used in operating activities was $2,259,097, compared with $1,154,192 in Q1 2023. Investing activities provided $3,445,523, primarily from U.S. Treasury bill maturities and sales, partially offset by purchases. Financing activities used $91,507 for deferred offering costs. Cash, cash equivalents, and restricted cash increased by $1,094,919 to $8,452,606.
Management reported working capital of $27,284,367 at March 31, 2024. The company had a $2.0 million revolving credit facility maturing July 26, 2024, but had made no drawdowns. The facility carried a variable rate initially calculated at 7.75%; the company stated that it was in compliance with all covenants.
Material Changes Versus the Prior Comparable Period
- Net loss attributable to MDB increased 285.1%, driven by higher compensation and other operating costs and a swing from an unrealized investment gain to an unrealized investment loss.
- Compensation expense increased by $4.02 million, primarily due to recognition of restricted stock compensation and hiring during the second half of 2023.
- Professional fees increased 52.0% on higher audit, tax, legal, consulting, and self-clearing implementation costs.
- The technology development segment generated no operating income in Q1 2024, compared with $59,159 in Q1 2023, which included a feasibility study.
- Invizyne’s net loss increased to $1,008,457 from $241,150, while net research and development costs increased because grant funding declined. Grant reimbursements remain subject to timing fluctuations.
- U.S. Treasury bill holdings declined by $3.28 million as securities were sold or matured to fund operations and liquidity needs.
- Segregated cash increased by $1.71 million, and clearing deposits increased by $443,740, reflecting customer deposits and increased self-clearing activity.
- Broker-dealer investments at fair value declined by $772,397, reflecting lower values of common stock and warrants.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
The filing does not provide quantitative earnings, revenue, or cash-flow guidance. Management expects grant funding to fluctuate and intends to use available capital for Invizyne development, identifying and developing partner companies, general corporate purposes, and working capital.
MDB’s broker-dealer subsidiary must maintain minimum net capital under SEC Rule 15c3-1. Public Ventures reported net capital of $6,285,959, or $6,035,959 above the $250,000 minimum. Its aggregate indebtedness-to-net-capital ratio was 0.98 to 1, compared with a permitted maximum of 15 to 1. These requirements may limit distributions to the parent company.
Public Ventures has uncapped indemnification obligations to its clearing broker for certain customer-related losses. The filing states that no material losses or outstanding obligations existed under this arrangement at March 31, 2024.
Invizyne’s research grants may be extended or replaced, but the latest identified grant was scheduled to expire August 31, 2024. Grant receipts depend on compliance with grant terms and eligible expenditures. The company also has potential future milestone payments under an exclusive license agreement totaling $600,000 if specified product sales thresholds are achieved.
MDB reported no pending or threatened material legal proceedings and no material subsequent events. Principal risks include investment valuation volatility, reliance on grants, technology-development and commercialization uncertainty, possible regulatory approval failures, capital-market conditions, recessionary conditions, related-party transactions, and the need for additional funding if partner technologies do not become commercially viable.
The company disclosed that its disclosure controls and procedures were not effective as of March 31, 2024 because of previously identified material weaknesses in internal control over financial reporting. Remediation efforts are ongoing and have not yet operated for a sufficient period to be considered complete.
Investment valuation is a notable source of earnings volatility. At March 31, 2024, Level 3 warrants were valued at $2,592,546 using a Black-Scholes model with weighted-average volatility of 99.60%.
Important Facts for Investors to Verify
- Confirm the composition and sustainability of operating income, as the filing does not present a clear consolidated revenue total and Q1 results were materially affected by unrealized investment losses.
- Assess whether the elevated compensation and stock-based compensation expense will continue; MDB reported $34.3 million of unrecognized expense for time-based RSUs and $13.5 million for performance- or market-based RSUs.
- Review liquidity after recurring operating cash burn, including the use of Treasury bills and the maturity or renewal of the $2.0 million revolving credit facility in July 2024.
- Monitor Public Ventures’ net-capital compliance, segregated customer funds, clearing deposits, and customer and non-customer payables as self-clearing operations expand.
- Evaluate the valuation sensitivity of broker-dealer warrants and other investments, particularly the Level 3 instruments.
- Track Invizyne’s grant renewals, grant receivables, research progress, commercial prospects, and potential license milestone payments.
- Follow remediation of the material weaknesses in internal control over financial reporting.
- Review related-party payments and transactions, including approximately $320,792 of related-party operating expenses reported for Q1 2024.